# A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct05227664/  
OnCo record `nct05227664` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AK117 in triple-negative breast cancer, run by Akeso, active and no longer recruiting.

## Summary

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT05227664 by Akeso, with 120 participants enrolled, started 2022-03-23 and due to reach its primary completion in 2026-12-30. Interventions recorded: AK117, AK112, Nab paclitaxel and paclitaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05227664
- Phase: 2
- Setting: A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
- Sponsor: Akeso
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05227664: https://clinicaltrials.gov/study/NCT05227664

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [AK117](https://onco.cc/drugs/ak117/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05227664.json